Cell Rep:揭示 病毒诱发细胞癌变的关键机制

2019-03-30 佚名 复旦大学基础医学院

近日,复旦大学基础医学院医学分子病毒学教育部卫健委重点实验室研究员蔡启良研究团队首次揭示了一种病毒介导AURKB蛋白水解切割调节机制及其在诱发宿主细胞恶性增殖中的重要调控作用。3月26日,研究成果以“Viral-mediated AURKB Cleavage Promote Cell Segregation and Tumorigenesis”为题在线发表于Cell Reports。

近日,复旦大学基础医学院医学分子病毒学教育部卫健委重点实验室研究员蔡启良研究团队首次揭示了一种病毒介导AURKB蛋白水解切割调节机制及其在诱发宿主细胞恶性增殖中的重要调控作用。3月26日,研究成果以“Viral-mediated AURKB Cleavage Promote Cell Segregation and Tumorigenesis”为题在线发表于Cell Reports。

AURKB是一种丝氨酸/苏氨酸蛋白激酶,在有丝分裂过程中负责染色体和胞质准确分离的关键调控。AURKB在多数实体瘤和血液肿瘤细胞中呈现异常高表达,被认为是重要的促癌因子。据统计,目前世界范围内超过1/5的肿瘤发生与病毒感染有关,其中人类γ-疱疹病毒(KSHV和EBV)感染淋巴瘤和皮肤肿瘤等多种恶性肿瘤发生密切相关, 是造成艾滋病患者等免疫力低下人群死亡的主要因素之一。但是,有关病毒是否影响AURKB蛋白功能诱发细胞恶变等问题尚不清楚。

该研究在前期累积工作基础上,进一步发现了KSHV、EBV和HPV等多种病毒相关肿瘤组织细胞中AURKB蛋白存在水解小分子多肽现象。研究团队以KSHV为模型,深入研究发现了病毒编码关键毒蛋白LANA可诱发AURKB多肽切割,并揭示了其主要依赖于丝氨酸蛋白酶在AURKB第76位天冬氨酸发挥切割活性。团队利用体内外活细胞实时成像等技术证实了切割后小分子多肽产物可显着加速染毒细胞有丝分裂进程及其恶性增殖。研究不仅揭示了病毒如何诱发宿主细胞恶变调控的新机制,同时也显示了AURKB多肽切割位点可作为一种抗肿瘤药物新干预靶点,其切割产物有望成为肿瘤分级和预后评价指标。

原始出处:

Zhu Q,et al.Viral-Mediated AURKB Cleavage Promotes Cell Segregation and Tumorigenesis.Cell Rep. 2019 Mar 26;26(13):3657-3671.e5.

评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1961489, encodeId=8ed11961489ca, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jul 07 03:32:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871210, encodeId=ea2e18e121004, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Apr 09 23:32:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978835, encodeId=c76819e88356f, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Jun 28 21:32:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557079, encodeId=d00a155e0797f, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Mon Apr 01 09:32:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363844, encodeId=f37f363844d4, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=00912551888, createdName=12543c13m83暂无昵称, createdTime=Sun Mar 31 07:30:59 CST 2019, time=2019-03-31, status=1, ipAttribution=)]
    2019-07-07 维他命

    #CEL#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1961489, encodeId=8ed11961489ca, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jul 07 03:32:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871210, encodeId=ea2e18e121004, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Apr 09 23:32:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978835, encodeId=c76819e88356f, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Jun 28 21:32:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557079, encodeId=d00a155e0797f, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Mon Apr 01 09:32:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363844, encodeId=f37f363844d4, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=00912551888, createdName=12543c13m83暂无昵称, createdTime=Sun Mar 31 07:30:59 CST 2019, time=2019-03-31, status=1, ipAttribution=)]
    2019-04-09 zhaozhouchifen

    #Cell#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1961489, encodeId=8ed11961489ca, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jul 07 03:32:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871210, encodeId=ea2e18e121004, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Apr 09 23:32:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978835, encodeId=c76819e88356f, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Jun 28 21:32:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557079, encodeId=d00a155e0797f, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Mon Apr 01 09:32:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363844, encodeId=f37f363844d4, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=00912551888, createdName=12543c13m83暂无昵称, createdTime=Sun Mar 31 07:30:59 CST 2019, time=2019-03-31, status=1, ipAttribution=)]
    2019-06-28 qingting

    #细胞癌#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1961489, encodeId=8ed11961489ca, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jul 07 03:32:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871210, encodeId=ea2e18e121004, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Apr 09 23:32:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978835, encodeId=c76819e88356f, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Jun 28 21:32:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557079, encodeId=d00a155e0797f, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Mon Apr 01 09:32:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363844, encodeId=f37f363844d4, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=00912551888, createdName=12543c13m83暂无昵称, createdTime=Sun Mar 31 07:30:59 CST 2019, time=2019-03-31, status=1, ipAttribution=)]
    2019-04-01 axin014

    #癌变#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1961489, encodeId=8ed11961489ca, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jul 07 03:32:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871210, encodeId=ea2e18e121004, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Apr 09 23:32:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978835, encodeId=c76819e88356f, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Jun 28 21:32:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557079, encodeId=d00a155e0797f, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Mon Apr 01 09:32:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363844, encodeId=f37f363844d4, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=00912551888, createdName=12543c13m83暂无昵称, createdTime=Sun Mar 31 07:30:59 CST 2019, time=2019-03-31, status=1, ipAttribution=)]
    2019-03-31 12543c13m83暂无昵称

    谢谢分享

    0